

Network Pharmacology and Molecular Docking Identify the Potential Mechanism and Therapeutic Role of *Scutellaria baicalensis* in Alzheimer's Disease

Yutao Peng¹, Chanjuan Zhou²

¹Department of Function, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China; ²Department of Clinical Psychology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, People's Republic of China

Correspondence: Chanjuan Zhou, Department of Clinical psychology, The First Affiliated Hospital, Hengyang Medical School, University of South China, 69 Chuan Shan Road, Hengyang, Hunan, 421001, People's Republic of China, Tel +86 13212694904, Email zhouchanjuan_86@163.com

Aim: *Scutellaria baicalensis*, a traditional Chinese medicinal herb renowned for its anti-inflammatory, antioxidant, and anti-tumor properties, has shown promise in alleviating cognitive impairment associated with Alzheimer's disease. Nonetheless, the exact neuroprotective mechanism of *Scutellaria baicalensis* against Alzheimer's disease remains unclear. In this study, network pharmacology was employed to explore the possible mechanisms by which *Scutellaria baicalensis* protects against Alzheimer's disease.

Methods: The active compounds of *Scutellaria baicalensis* were retrieved from the TCMSP database, and their corresponding targets were identified. Alzheimer's disease-related targets were obtained through searches in the GeneCards and OMIM databases. Cytoscape 3.6.0 software was utilized to construct a regulatory network illustrating the "active ingredient-target" relationships. Subsequently, the target genes affected by *Scutellaria baicalensis* in the context of Alzheimer's disease were input into the String database to establish a PPI network. GO analysis and KEGG analysis were conducted using the DAVID database to predict the potential pathways associated with these key targets. Following this, the capacity of these active ingredients to bind to core targets was confirmed through molecular docking. In vitro experiments were then carried out for further validation.

Results: A total of 36 active ingredients from *Scutellaria baicalensis* were screened out, which corresponded to 365 targets. Molecular docking results demonstrated the robust binding abilities of Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone to key target proteins (SRC, PIK3R1, and STAT3). In vitro experiments showed that the active components of *Scutellaria baicalensis* can inhibit STAT3 expression by downregulating the PIK3R1/SRC pathway in Neuro 2A cells.

Conclusion: In summary, these findings collectively suggest that *Scutellaria baicalensis* holds promise as a viable treatment option for Alzheimer's disease.

Keywords: *Scutellaria baicalensis*, Alzheimer's disease, network pharmacology, molecular docking

Introduction

Alzheimer's disease is a prevalent neurodegenerative disorder, accounting for 50% to 75% of dementia cases, with no current cure available.^{1,2} Patients with Alzheimer's disease exhibit clinical manifestations such as memory impairment, cognitive decline, behavioral disturbances, and impaired daily functioning.^{3,4} There is an urgent demand for effective treatments for Alzheimer's disease. Presently, drugs targeting cholinergic and glutamatergic neurotransmission are the mainstay of Alzheimer's treatment, offering symptom relief but with contentious neuroprotective effects.^{5,6} Consequently, the search for novel Alzheimer's treatments remains imperative. Traditional Chinese medicine, with a history spanning over 2500 years in the Chinese healthcare system, has revealed numerous bioactive compounds within Chinese herbs that have demonstrated efficacy in treating various ailments. Of notable significance, traditional Chinese medicine has emerged as a promising approach for addressing the treatment of Alzheimer's disease.⁷⁻⁹

Scutellaria baicalensis, an herb belonging to the platycodon family, is commonly used in the treatment of bacterial pneumonia, colds, and insomnia. Recently, numerous chemical, pharmacological, and clinical investigations have demonstrated its neuroprotective,^{10–12} anti-tumor,¹³ antioxidant,^{14,15} and anti-inflammatory¹⁶ properties. Notably, it has been reported that *Scutellaria baicalensis* attenuates neuronal loss and improves memory and neuroplasticity disorders in rats with Alzheimer's disease.^{17,18} However, the comprehensive mechanism of *Scutellaria baicalensis* intervention in Alzheimer's disease remains unclear, with limited research at the molecular level. Alzheimer's disease is influenced by alterations in multiple gene expressions; therefore, drugs targeting a single pathway may not yield optimal therapeutic outcomes for Alzheimer's disease. Network pharmacology offers a systematic approach to study the multi-component, multi-target, and multi-pathway mechanisms underlying drug treatment through network visualization diagrams based on existing biological data. This aligns with the holistic principles of traditional Chinese medicine, which emphasize overall disease management and provide novel insights and methodologies for studying complex disease mechanisms.^{19–21} Molecular docking employs computer technology to explore spatial structure interactions between drug molecules and targets, enabling the targeted design of appropriate drugs.^{22,23} In this study, we employed network pharmacology and molecular docking approaches to elucidate the target proteins involved along with related pathways and mechanisms underlying *Scutellaria baicalensis* intervention in Alzheimer's disease.

Methods

Obtaining the Active Ingredients and Targets of *Scutellaria baicalensis*

The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database (<https://tcmsp-e.com/tcmstp.php>) was used to screen the main components of *Scutellaria baicalensis*. According to the TCMSP database recommendation, the main ingredients of *Scutellaria baicalensis* with “oral bioavailability (OB) > 30% and drug-likeness (DL) \geq 0.18” were selected. Based on the data obtained by screening the TCMSP database and, at the same time, consulting relevant literature for supplementation, the active ingredients of *Scutellaria baicalensis* were finally determined. Subsequently, the 3D structures of all compounds were built using 3D Viewer and saved in mol2 file format for target prediction. Finally, target information was obtained from the TCMSP database based on feature data and physicochemical parameters, followed by the retrieval of SMILES files for these active ingredients from the PubChem database. These SMILES files are utilized in target prediction through the SwissTargetPrediction (STP) website (<http://old.swisstargetprediction.ch/>). The combined targets derived from both the TCMSP and STP databases represent the main targets of active ingredients in *Scutellaria baicalensis*.

Identification of Targets Associated with Alzheimer's Disease

Initially, the keyword “Alzheimer” was employed to screen established therapeutic targets for Alzheimer's disease from both the Online Mendelian Inheritance in Man (OMIM) (<https://omim.org/>) and GeneCards (<https://www.genecards.org/>).

Construction of Active Ingredient-Target Network

The Venn diagram online tool (<https://bioinfogp.cnb.csic.es/tools/venny/>) was utilized to identify the common targets of *Scutellaria baicalensis* and Alzheimer's disease by intersecting the targets related to Alzheimer's disease and those related to active ingredients. Subsequently, a Venn diagram was generated. The intersection genes represented potential targets of *Scutellaria baicalensis* for the treatment of Alzheimer's disease. The target proteins for active ingredients and Alzheimer's disease were predicted, and standardized naming (gene name) was applied. The selected Alzheimer's disease targets were imported into the Cytoscape 3.7.1 software to generate an ingredient-target network map.

Construction of the Protein-Protein Interaction (PPI) Network and Identification of Core Targets

The obtained intersection target protein was uploaded to the STRING database, with the species selected as “Homo sapiens” to retrieve PPI information. The resulting data file in Tab Separated Values (TSV) format was exported and

imported into the Cytoscape 3.8.2 software for visualization processing. Within Cytoscape, CytoHubba, a built-in plugin, was utilized for network analysis based on 11 topology methods derived from shortest path algorithms, including degree, edge penetration component, maximum neighborhood component density, maximum group centrality, and six centralities (bottleneck, degree, betweenness, radiality, closeness, and stress). Among these methods, the maximum clique centrality (MCC) algorithm has been proven to be more accurate in predicting important targets. By employing the MCC topology algorithm in this study, key core targets were identified as crucial nodes representing *Scutellaria baicalensis*'s therapeutic effects against Alzheimer's disease. Furthermore, key sub-networks of active ingredients from *Scutellaria baicalensis* were constructed within the PPI network, which plays a significant role.

Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway and Gene Ontology (GO) Enrichment Analysis

The obtained target genes were subjected to online analysis using the DAVID database, followed by importing them into Omicsbean software. The ID type was set as Gene Symbol, and the species was specified as "Homo sapiens". Subsequently, GO enrichment and KEGG pathway analyses were conducted on the target proteins. The resulting output file was imported into an Excel worksheet for further screening of functions and pathways with a significance level of $P < 0.05$, which was then visualized in a bar chart.

Validation of Drug-Component-Target-Disease Network

The drug-component-target-disease network was created through the Cytoscape 3.7.1 software by combining the shared genes from the disease and drug datasets with the top 20 pathways identified through KEGG analysis.

Molecular Docking

Molecular docking is a process that simulates the docking posture of small molecules at the active sites of large molecules to predict affinity. In this study, AutoDock4 was employed for molecular docking analysis between the potential active ingredients of *Scutellaria baicalensis* and their targets. The active ingredients of *Scutellaria baicalensis* were obtained from the PubChem database in SDF format, and their 3D structure was constructed using ChemOffice software, followed by energy minimization and conversion to mol2 format. In terms of target proteins, their 3D structure was retrieved from the PDB database (<http://www.rcsb.org/>) and processed using pymol 2.3 to remove water molecules and AutoDock4 to add hydrogen atoms. Both the compound and target were saved in pdbqt format for subsequent docking analysis with the V program. Finally, ligplot2.23 generated a 2D interaction diagram, while pymol 2.3 analyzed the 3D model diagram of the docking complex.










Cell Culture

The Neuro 2A cells, sourced from Procell Life Science & Technology Co., Ltd. in Wuhan, China, were cultured in Dulbecco's Modified Eagle's Medium (DMEM). The growth medium consisted of 10% fetal bovine serum (FBS), 100 U/mL streptomycin, and 100 U/mL penicillin. Cultivation was carried out under conditions of 5% CO₂ at 37 °C. Following this, the cells were subjected to treatment with Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone, all at a concentration of 80 μM, for a duration of 12 hours.

Cell Activity Detection










Baicalein (CAS No. 491-67-8), Wogonin (CAS No. 632-85-9), and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone (CAS No. 86926-52-5) were procured from Baoji Chenguang Biotechnology Co., Ltd. (China). To assess cell viability, we employed the Counting Kit-8 (CCK-8) assay. In brief, Neuro 2A cells were initially seeded into 96-well culture plates and allowed to incubate for 12 hours at 37°C. Subsequently, the cells underwent treatment with various concentrations of Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone (ranging from 0 to 160 μM) for a duration of 24 hours. Following this treatment, a 10 μL aliquot of CCK-8 solution was added to each well and incubated for an additional hour at 37°C. The absorbance at 450 nm was then measured using a 96-well microplate reader (Bio-Tek Instruments Inc.,

Table I Active Ingredients in *Scutellaria baicalensis*

Serial Number	CAS	Active Ingredients	Chemical Structure
MOL002714	491-67-8	Baicalein	
MOL000552	86926-52-5	5,2'-Dihydroxy-6,7,8-trimethoxyflavone	
MOL000173	632-85-9	Wogonin	
MOL002934	55084-08-7	NEOBAICALEIN	
MOL002932	41060-16-6	Panicolin	
MOL012246	57096-02-3	5,7,4'-trihydroxy-8-methoxyflavanone	
MOL002927	55084-08-7	Skullcapflavone II	
MOL002911	N/A	2,6,2',4'-tetrahydroxy-6'-methoxychaleone	
MOL002937	18956-18-8	DIHYDROOROXYLIN	










(Continued)

Table 1 (Continued).

Serial Number	CAS	Active Ingredients	Chemical Structure
MOL000228	1090-65-9	(2R)-7-hydroxy-5-methoxy-2-phenylchroman-4-one	
MOL002915	19103-54-9	Salvigenin	
MOL000073	35323-91-2	Ent-Epicatechin	
MOL002917	N/A	5,2',6'-Trihydroxy-7,8-dimethoxyflavone	
MOL008206	3570-62-5	Moslosooflavone	
MOL000449	83-48-7	Stigmasterol	
MOL001490	N/A	bis[(2S)-2-ethylhexyl] benzene-1,2-dicarboxylate	
MOL002879	25103-50-8	Diop	
MOL002897	1816-59-8	Epiberberine	










(Continued)

Table 1 (Continued).

Serial Number	CAS	Active Ingredients	Chemical Structure
MOL002928	480-11-5	Oroxylin a	
MOL002914	4049-38-1	Eriodyctiol (flavanone)	
MOL002910	479-54-9	Carthamidin	
MOL002913	N/A	Dihydrobaicalin_qt	
MOL000525	N/A	Norwogonin	
MOL010415	N/A	11,13-Eicosadienoic acid, methyl ester	
MOL002926	18956-18-8	Dihydrooroxylin A	
MOL012266	70028-59-0	Rivularin	
MOL002925	82475-00-1	5,7,2',6'-Tetrahydroxyflavone	

(Continued)

Table 1 (Continued).

Serial Number	CAS	Active Ingredients	Chemical Structure
MOL002908	77056-20-3	5,8,2'-Trihydroxy-7-methoxyflavone	
MOL000358	83-46-5	Beta-sitosterol	
MOL000359	83-46-5	Sitosterol	
MOL012245	N/A	5,7,4'-trihydroxy-6-methoxyflavanone	
MOL002933	57096-02-3	5,7,4'-Trihydroxy-8-methoxyflavone	
MOL001689	480-44-4	Acacetin	
MOL002909	N/A	5,7,2,5-tetrahydroxy-8,6-dimethoxyflavone	
MOL001506	111-02-4	Supraene	
MOL001458	3486-66-6	Coptisine	

Construction of the Compound-Target Network

Potential targets of *Scutellaria baicalensis* were mapped with Alzheimer's disease-related targets, and a total of 176 intersection targets were obtained by the Venn platform (Figure 1). Then, active components and intersection targets were imported into the Cytoscape 3.8.2 software for visual analysis, and the diagram of the "compound-target network" was obtained (Figure 2). The analysis presented in Figure 2 reveals that certain targets are subject to modulation by multiple active compounds, whereas others exhibit responsiveness to only one compound (eg, RPS6KB2, SAE1, ROCK2, QPCT et al). Notably, SRC, PIK3R1, ESR1, EGFR, STAT3, and other targets demonstrate susceptibility to regulation by all of the compounds.

Construction of the PPI Network

To elucidate the mechanism by which *Scutellaria baicalensis* protects against Alzheimer's disease, we began by inputting the intersection targets into the String database. The species was specified as "Homo sapiens", while the other parameters were left at their default settings. As shown in Figure 3A, the network linking drug targets and disease targets comprises 176 nodes and 302 edges. Notably, the network exhibited an average node degree of 10.4 and a local clustering coefficient of 0.900. Subsequently, we imported the network data into Cytoscape 3.7.2 software, where we employed the NetworkAnalyzer plug-in tool to generate a PPI network diagram (Figure 3B). This diagram was constructed based on the density values, or degrees, of the nodes within the network. Larger nodes in the diagram corresponded to genes with higher degrees. As shown in Figure 3C, the top 10 proteins were ranked by their degree centrality (Degree, Betweenness, and Closeness). Among them, SRC, PIK3R1, and STAT3 were determined by taking the intersection of targets obtained through these three methods (Figure 4A). Within *Scutellaria baicalensis*, Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone had a significant correlation with these key targets. (Figure 4B). These proteins are of paramount importance in PPI and represent the core targets of *Scutellaria baicalensis*' active ingredients in combating Alzheimer's disease.

Pathway Enrichment Analysis

Next, GO and KEGG enrichment analyses were performed to identify biological functions and metabolic pathways associated with cross-targets. The bubble plot results obtained from the KEGG enrichment analysis illustrated in Figure 5




Figure 1 Intersection of target genes between the active ingredients of *Scutellaria baicalensis* and those linked to Alzheimer's disease.




Figure 2 Active ingredients-target network construction. The dark green circular node represents active ingredients of *Scutellaria baicalensis*, and the other nodes represent the targets.

demonstrate the impact of *Scutellaria baicalensis* on Alzheimer’s disease. Out of the 166 identified pathways, we focused our comparative analysis on 20 of them. These pathways are closely associated with a range of pathophysiological processes, including Alzheimer’s disease, cancer, atherosclerosis, insulin resistance, and endocrine resistance. To visualize the key pathways and associated targets identified through KEGG enrichment analysis, we employed Cytoscape software to construct a “target-pathway” network diagram, which is depicted in Figure 6. Additionally, for a comprehensive perspective on metabolic pathways relevant to Alzheimer’s disease, we integrated data from KEGG and the Genome Encyclopedia to generate Figure 7.

Then, we imported the set of 176 targets into the Metascape platform and subsequently conducted a GO functional enrichment analysis to identify the top 10 entries of significance. The outcomes of the GO enrichment analysis unveiled




Figure 3 The protein-protein interaction (PPI) network of *Scutellaria baicalensis* in the treatment of Alzheimer's disease. **(A)** PPI network constructed by STRING. **(B)** PPI network established by Cytoscape 3.6.0. **(C)** Frequency histogram of the top 10 genes based on degree values.




Figure 4 Screening of key targets. **(A)** the intersection of key targets obtained through degree centrality (Degree, Betweenness, and Closeness). **(B)** Heat map illustrating the binding affinities of the active ingredients to key targets from molecular docking.

a comprehensive range of molecular function (MF) pathways, totaling 163. These pathways encompassed critical functions such as identical protein binding, ATP binding, protein serine/threonine/tyrosine kinase activity, protein kinase activity, kinase activity, protein tyrosine kinase activity, heme binding, transmembrane receptor protein tyrosine kinase activity, RNA polymerase II transcription factor activity, and ligand-activated sequence-specific DNA binding. Regarding biological processes (BPs), the 711 pathways enriched by the common genes indicated that the therapeutic effects of *Scutellaria baicalensis* on Alzheimer's disease involve diverse processes such as protein phosphorylation, response to xenobiotic stimulus, protein autophosphorylation, peptidyl-serine phosphorylation, transmembrane receptor protein tyrosine kinase signaling pathway, and positive regulation of the MAPK cascade. Furthermore, a total of 107 cellular components (CCs) were identified in the enrichment analysis. These components encompassed structures like the plasma membrane, cytoplasm, neuronal cell body, axon, and dendrite, as depicted in Figure 8.




Figure 5 Enrichment analysis of KEGG biological pathways.

Molecular Docking Analysis

To investigate the interaction between *Scutellaria baicalensis*' active ingredients and target genes, we employed Autodock and Pymol software for molecular docking. Specifically, we conducted docking simulations involving three critical targets and three active components of *Scutellaria baicalensis*, recording the corresponding binding energies (Figure 4B). The planar structures of Baicalein, 5,2'-Dihydroxy-6,7,8-trimethoxyflavone, and Wogonin in silico active compounds can be seen in Figure 9A–C, respectively. The results of molecular docking demonstrated the facile entry and binding of all three active ingredients within the active pocket regions of SRC, PIK3R1, and STAT3 proteins, as shown in Figures 10–12. The docking results of these active ingredients and three targets were refined via investigating the specific binding sites in the UCFS chimera. Specifically, in PIK3R1, Baicalein had hydrogen bonds with amino acid residues ASN-47 and ARG-34. In SRC, Baicalein and amino acid residues GLU-160, HIS-204, and LY-S155 had hydrogen bonds. In STAT3, Baicalein had hydrogen bonds with amino acid residues in TYR-657. The hydrogen bonds between Wogonin and the amino acid residues GLU-94 and HIS-96 were observed in PIK3R1. In SRC, Wogonin formed hydrogen bonds with amino acid residues of LYS-155. In STAT3, Wogonin had hydrogen bonds with amino acid residues of TYR-657. The compound 5,2'-Dihydroxy-6,7,8-trimethoxyflavone established hydrogen bonds with the amino acid residues located at HIS-96, LEU-132, PRO-98, and LEU-129 in PIK3R1. In SRC, 5,2'-Dihydroxy-6,7,8-trimethoxyflavone formed hydrogen bonds with amino acid residues of HIS-204 and LYS-206. In STAT3, 5,2'-Dihydroxy-6,7,8-trimethoxyflavone had hydrogen bonds with amino acid residues of THR-443. These findings further confirm that the active ingredients of *Scutellaria baicalensis* have a good binding effect on their targets.

Effect of *Scutellaria baicalensis*' Active Ingredients on the Expression of Target Genes

The emergence of several cell lines, such as the rat pheochromocytoma (PC12) cell line, adipose mesenchymal stem cell, SH-SY5Y cells, and Neuro 2A cells, has provided valuable models for studying Alzheimer's disease-related processes and investigating the neuroprotective effects of various compounds.²⁴ Among them, Neuro 2A cells have been widely used to study neuronal differentiation, cell signaling pathways, and A β metabolism during Alzheimer's disease. These cells provide a valuable model for exploring the cellular mechanisms involved in





Figure 6 Target-pathway network diagram.

Alzheimer's disease pathology and evaluating the therapeutic potential of various compounds. To investigate the impact of active ingredients from *Scutellaria baicalensis* on the expression of their target genes, we conducted both qRT-PCR and CCK-8 assays. The results of the CCK-8 assay demonstrated that treatment with 80 μ M Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone did not induce cytotoxic effects in Neuro 2A cells (Figure 13A). Consequently, we proceeded with a concentration of 80 μ M for subsequent experiments. Figure 13B–D showed that the active ingredients of *Scutellaria baicalensis* (Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone) significantly decreased the expression levels of SRC, PIK3R1, and STAT3. STAT3 is known as a substrate of the non-receptor tyrosine kinase SRC.²⁵ Our results also demonstrated that Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone decreased STAT3 levels via inhibiting the PIK3R1/SRC pathway (Supplementary Figures 1–3). These results indicate that *Scutellaria baicalensis*' active components can suppress the expression of their target genes in Neuro 2A cells, reinforcing the outcomes from network pharmacology and molecular docking analyses.



03010 3/11/21
 © Kanehisa Laboratories

Figure 7 Signaling pathways by which *Scutellaria baicalensis* protects against Alzheimer’s disease. The highlighted red labeled nodes represent the core targets of *Scutellaria baicalensis* in treating Alzheimer’s disease. Other nodes represent relevant targets involved in the pathogenesis of Alzheimer’s disease. The pathways presented were summarized using the KEGG pathway database.

Discussion

As a commonly used traditional tonic medicine, *Scutellaria baicalensis* possesses neuroprotective, anti-tumor, and mood-enhancing properties.^{26,27} The anti-Alzheimer’s disease mechanism of *Scutellaria baicalensis* was elucidated in this study using network pharmacology and molecular docking techniques. Traditional Chinese medicine adopts a holistic perspective in its development. Network pharmacology serves as a systems biology approach for disease




Figure 8 GO enrichment analysis.

treatment by reflecting the concept of multi-component, multi-target, and multi-pathway regulation. Molecular docking utilizes computational simulations to design drugs with targeted effects. Therefore, the application of network pharmacology and molecular docking technology plays a crucial role in elucidating the therapeutic mechanisms underlying complex diseases treated with *Scutellaria baicalensis*. A total of 176 core targets were individually examined through functional enrichment analysis using the GO and KEGG databases. The results showed that protein binding was the most enriched item in GO analysis, indicating that *Scutellaria baicalensis* may




Figure 9 The planar structures of the in silico active ingredients. **(A)** Baicalein; **(B)** 5,2'-Dihydroxy-6,7,8-trimethoxyflavone; **(C)** Wogonin.




Figure 10 Molecular docking model of PIK3R1-active ingredients. **(A)** PIK3R1-Baicalein; **(B)** PIK3R1-Wogonin; **(C)** PIK3R1-5,2'-Dihydroxy-6,7,8-trimethoxyflavone.




Figure 11 Molecular docking model of SRC-active ingredients. **(A)** SRC-Baicalein; **(B)** SRC-Wogonin; **(C)** SRC-5,2'-Dihydroxy-6,7,8- trimethoxyflavone.

interfere with Alzheimer's disease progression by modulating protein-protein interactions. Among the 166 KEGG pathways analyzed, Alzheimer's disease-related genes were predominantly enriched in pathways in the KEGG category, suggesting that *Scutellaria baicalensis* intervention in Alzheimer's disease might exert its effects through regulating signaling pathways associated with Alzheimer's disease.

The interference of active ingredients of *Scutellaria baicalensis* on neurodegenerative disease has been reported.^{18,28,29} Our study revealed that Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone in *Scutellaria baicalensis* also exhibit significant intervention effects on Alzheimer's disease. Molecular docking analysis further identified Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8-trimethoxyflavone as key players in the intervention of Alzheimer's disease by effectively binding to SRC, PIK3R1, and STAT3. These targets are crucial for the pharmacodynamic effects exerted by *Scutellaria baicalensis*' active ingredients and play pivotal roles in the




Figure 12 Molecular docking model of STAT3-active ingredients. **(A)** STAT3-Baicalein; **(B)** STAT3-Wogonin; **(C)** STAT3-5,2'-Dihydroxy-6,7,8- trimethoxyflavone.

pathogenesis and progression of Alzheimer's disease. It has been reported that suppression of SRC mitigates amyloid-associated microgliosis and attenuates the inflammation response in a murine model of Alzheimer's disease.^{30,31} PIK3R1 induces the deposition of tau and A β and disrupts the insulin signaling pathway in the brain of patients with Alzheimer's disease.^{32,33} Moreover, STAT3 inhibition protects against neuroinflammation and decreases β -amyloid levels and plaque burden in an Alzheimer's disease model.^{34,35} Notably, our findings showed that the active ingredients of *Scutellaria baicalensis* inhibit STAT3 expression by downregulating the PIK3R1/SRC pathway. Collectively, these findings imply that *Scutellaria baicalensis* guards against Alzheimer's disease in vitro through the inhibition of these specific targets.




Figure 13 The active ingredients of *Scutellaria baicalensis* inhibit the expression of key target genes. Cell viability was measured by the CCK-8 assay. **(A)** Neuro 2A cells were treated with Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8- trimethoxyflavone at 0 μM, 10 μM, 20 μM, 40 μM, 80 μM, and 160 μM. Neuro 2A cells were treated with Baicalein, Wogonin, and 5,2'-Dihydroxy-6,7,8- trimethoxyflavone at 80 μM. **(B–D)** The real-time qRT-PCR analysis of the mRNA levels of PIK3R1, SRC, and STAT3 in Neuro 2A cells treated with active ingredients. * $p < 0.05$, ** $p < 0.01$ vs Model, # $p < 0.05$ vs Baicalein and 5,2'-Dihydroxy-6,7,8- trimethoxyflavone.

Conclusion

The present study found that active ingredients of *Scutellaria baicalensis* protect against Alzheimer's disease through inhibiting the PIK3R1/SRC/STAT3 pathway in Neuro 2A cells by integrating network pharmacology, molecular docking, and experimental verification. These findings provide evidence for the potential therapeutic effect of *Scutellaria baicalensis* on Alzheimer's disease, offering valuable insights for future clinical drug development.

Data Sharing Statement

The corresponding author can provide access to the datasets used and/or analyzed in the current study upon request through a reasonable means of communication.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of Parkinson's disease. *Lancet*. 2024;403(10423):283–292. PubMed PMID: 38245248. doi:10.1016/s0140-6736(23)01419-8
2. Diaz-Galvan P, Przybelski SA, Algeciras-Schimmich A, et al. Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies. *Alzheimers Dement*. 2024. PubMed PMID: 38329197. doi:10.1002/alz.13653
3. Florian H, Wang D, Arnold SE, et al. Tilavonemab in early Alzheimer's disease: results from a Phase 2, randomized, double-blind study. *Brain*. 2023;146(6):2275–2284. PubMed PMID: 36730056; PubMed Central PMCID: PMCPCMC10232284. doi:10.1093/brain/awad024
4. Landau SM, Lee J, Murphy A, et al. Individuals with Alzheimer's disease and low tau burden: characteristics and implications. *Alzheimers Dement*. 2024. PubMed PMID: 38241084. doi:10.1002/alz.13609
5. O'Leary K. Modeling real-world data to repurpose drugs for Alzheimer's disease. *Nature Med*. 2024. PubMed PMID: 38238602. doi:10.1038/d41591-024-00003-7
6. Nemy M, Dyrba M, Brosseron F, et al. Cholinergic white matter pathways along the Alzheimer's disease continuum. *Brain*. 2023;146(5):2075–2088. PubMed PMID: 36288546; PubMed Central PMCID: PMCPCMC10151179. doi:10.1093/brain/awac385
7. Liu C, Zhang L, Li Y, Li M, Han H, Wang K. Traditional Chinese Patent Medicine in the treatment of Alzheimer's disease: a systematic review and network meta-analysis. *Am J Chin Med*. 2023;51(3):517–546. PubMed PMID: 36866797. doi:10.1142/s0192415x2350026x
8. Yan H, Feng L, Li M. The role of Traditional Chinese Medicine Natural Products in β -amyloid deposition and tau protein hyperphosphorylation in Alzheimer's disease. *Drug Des Devel Ther*. 2023;17:3295–3323. PubMed PMID: 38024535; PubMed Central PMCID: PMCPCMC10655607. doi:10.2147/dddt.S380612
9. Lei X, Xu H, Wang Y, et al. Integrating network pharmacology and component analysis to study the potential mechanisms of Qi-Fu-Yin Decoction in Treating Alzheimer's disease. *Drug Des Devel Ther*. 2023;17:2841–2858. PubMed PMID: 37727255; PubMed Central PMCID: PMCPCMC10506672. doi:10.2147/dddt.S402624
10. Seo HW, Ha TY, Ko G, et al. Scutellaria baicalensis attenuated neurological impairment by regulating programmed cell death pathway in ischemic stroke mice. *Cells*. 2023;12(17). PubMed PMID: 37681864; PubMed Central PMCID: PMCPCMC10486384. doi:10.3390/cells12172133
11. Delerue T, Fátima Barroso M, Dias-Teixeira M, Figueiredo-González M, Delerue-Matos C, Grosso C. Interactions between Ginkgo biloba L. and Scutellaria baicalensis Georgi in multicomponent mixtures towards cholinesterase inhibition and ROS scavenging. *Food Res Int*. 2021;140:109857. PubMed PMID: 33648175. doi:10.1016/j.foodres.2020.109857
12. Huang J, Zhang X, Yang X, et al. Baicalin exerts neuroprotective actions by regulating the Nrf2-NLRP3 axis in toxin-induced models of Parkinson's disease. *Chem Biol Interact*. 2024;387:110820. PubMed PMID: 38016618. doi:10.1016/j.cbi.2023.110820
13. Liu H, Liu H, Zhou Z, et al. Scutellaria baicalensis enhances 5-fluorouracil-based chemotherapy via inhibition of proliferative signaling pathways. *Cell Commun Signal*. 2023;21(1):147. PubMed PMID: 37337282; PubMed Central PMCID: PMCPCMC10278337. doi:10.1186/s12964-023-01156-7
14. Zhang S, Lv H, Cai X, et al. Effects of the compound extracts of Caprifoliaceae and Scutellaria baicalensis Georgi on the intestinal microbiota and antioxidant function. *Front Microbiol*. 2023;14:1289490. PubMed PMID: 38282732; PubMed Central PMCID: PMCPCMC10822692. doi:10.3389/fmicb.2023.1289490
15. Jalili S, Panji M, Mahdavi-mehr M, et al. Enhancing anti-amyloidogenic properties and antioxidant effects of Scutellaria baicalensis polyphenols through novel nanoparticle formation. *Int J Biol Macromol*. 2024;262(Pt 1):130003. PubMed PMID: 38325696. doi:10.1016/j.ijbiomac.2024.130003
16. Gao L, Zhao JX, Qin XM, Zhao J. The ethanol extract of Scutellaria baicalensis Georgi attenuates complete Freund's adjuvant (CFA)-induced inflammatory pain by suppression of P2X3 receptor. *J Ethnopharmacol*. 2023;317:116762. PubMed PMID: 37301308. doi:10.1016/j.jep.2023.116762
17. Zhang H, Liu QQ, Ding SK, Li H, Shang YZ. Flavonoids from stems and leaves of Scutellaria baicalensis Georgi improve composited A β -induced Alzheimer's disease model rats' memory and neuroplasticity disorders. *Comb Chem High Throughput Screen*. 2023;26(8):1519–1532. PubMed PMID: 36200197. doi:10.2174/1386207325666221003092627
18. Wang R, Shen X, Xing E, Guan L, Xin L. Scutellaria baicalensis stem-leaf total flavonoid reduces neuronal apoptosis induced by amyloid beta-peptide (25–35). *Neural Regen Res*. 2013;8(12):1081–1090. PubMed PMID: 25206402; PubMed Central PMCID: PMCPCMC4145899. doi:10.3969/j.j.issn.1673-5374.2013.12.003
19. Jiashuo WU, Fangqing Z, Zhuangzhuang LI, Weiyi J, Yue S. Integration strategy of network pharmacology in Traditional Chinese Medicine: a narrative review. *J Tradit Chin Med*. 2022;42(3):479–486. PubMed PMID: 35610020; PubMed Central PMCID: PMCPCMC9924699. doi:10.19852/j.cnki.jtcm.20220408.003
20. Zhao L, Zhang H, Li N, et al. Network pharmacology, a promising approach to reveal the pharmacology mechanism of Chinese medicine formula. *J Ethnopharmacol*. 2023;309:116306. PubMed PMID: 36858276. doi:10.1016/j.jep.2023.116306
21. Li X, Liu Z, Liao J, Chen Q, Lu X, Fan X. Network pharmacology approaches for research of Traditional Chinese Medicines. *Chin J Nat Med*. 2023;21(5):323–332. PubMed PMID: 37245871. doi:10.1016/s1875-5364(23)60429-7
22. Yang WG, Sun A, Zhu R, Liu N, He WJ, Liu LL. Exploration of artemisinin against IgA nephropathy via AKT/Nrf2 pathway by bioinformatics and experimental validation. *Drug Des Devel Ther*. 2023;17:1679–1697. PubMed PMID: 37309415; PubMed Central PMCID: PMCPCMC10257916. doi:10.2147/dddt.S403422
23. Qi D, Li H, Liang C, et al. Herb-drug interaction of Xingnaojing injection and Edaravone via pharmacokinetics, mixed inhibition of UGTs, and molecular docking. *Phytomedicine*. 2023;112:154696. PubMed PMID: 36764095. doi:10.1016/j.phymed.2023.154696
24. Vicente-Zurdo D, Rosales-Conrado N, León-González ME. Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: a bioanalytical review. *Talanta*. 2024;269:125519. PubMed PMID: 38086100. doi:10.1016/j.talanta.2023.125519
25. Li X, Mak VCY, Zhou Y, et al. Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. *Nat Commun*. 2019;10(1):716. PubMed PMID: 30755611; PubMed Central PMCID: PMCPCMC6372715. doi:10.1038/s41467-019-08574-7
26. Xiang L, Gao Y, Chen S, Sun J, Wu J, Meng X. Therapeutic potential of Scutellaria baicalensis Georgi in lung cancer therapy. *Phytomedicine*. 2022;95:153727. PubMed PMID: 34535372. doi:10.1016/j.phymed.2021.153727
27. Limanaqi F, Biagioni F, Busceti CL, Polzella M, Fabrizi C, Fornai F. Potential antidepressant effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea. *Antioxidants*. 2020;9(3). PubMed PMID: 32178272; PubMed Central PMCID: PMCPCMC7139475. doi:10.3390/antiox9030234

28. Liu QQ, Ding SK, Zhang H, Shang YZ. The molecular mechanism of *Scutellaria baicalensis georgi* stems and leaves flavonoids in promoting neurogenesis and improving memory impairment by the PI3K-AKT-CREB signaling pathway in rats. *Comb Chem High Throughput Screen.* **2022**;25(5):919–933. PubMed PMID: 33966617. doi:10.2174/1386207324666210506152320
29. Shengkai D, Yazhen S. Flavonoids from stems and leaves of *Scutellaria baicalensis georgi* regulate the brain tau hyperphosphorylation at multiple sites induced by composed A β in rats. *CNS Neurol Disord Drug Targets.* **2022**;21(4):367–374. PubMed PMID: 34455972. doi:10.2174/1871527320666210827112609
30. Dhawan G, Combs CK. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease. *J Neuroinflammation.* **2012**;9:117. PubMed PMID: 22673542; PubMed Central PMCID: PMC3388011. doi:10.1186/1742-2094-9-117
31. Portugal CC, Almeida TO, Socodato R, Relvas JB. Src family kinases (SFKs): critical regulators of microglial homeostatic functions and neurodegeneration in Parkinson's and Alzheimer's diseases. *FEBS J.* **2022**;289(24):7760–7775. PubMed PMID: 34510775. doi:10.1111/febs.16197
32. Li H, Liu H, Lutz MW, Luo S. Novel genetic variants in TP37, PIK3R1, CALM1, and PLCG2 of the neurotrophin signaling pathway are associated with the progression from mild cognitive impairment to Alzheimer's disease. *J Alzheimers Dis.* **2023**;91(3):977–987. PubMed PMID: 36530083; PubMed Central PMCID: PMC9905310. doi:10.3233/jad-220680
33. Qian XH, Liu XL, Chen SD, Tang HD. Identification of immune hub genes associated with braak stages in Alzheimer's disease and their correlation of immune infiltration. *Front Aging Neurosci.* **2022**;14:887168. PubMed PMID: 35619939; PubMed Central PMCID: PMC9129065. doi:10.3389/fnagi.2022.887168
34. Reichenbach N, Delekate A, Plescher M, et al. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer's disease model. *EMBO Mol Med.* **2019**;11(2). PubMed PMID: 30617153; PubMed Central PMCID: PMC6365929. doi:10.15252/emmm.201809665
35. Choi M, Kim H, Yang EJ, Kim HS. Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease. *J Pharmacol Sci.* **2020**;143(4):290–299. PubMed PMID: 32507685. doi:10.1016/j.jphs.2020.05.009

Drug Design, Development and Therapy

Dovepress

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>